Drug-Drug Interactions and Initial Dosage Optimization of Quetiapine in Patients with Depression: A Real-World Study.

OBJECTIVE

Quetiapine has been used for treating patients with depression; however, drug-drug interactions (DDIs) deeply limit its individualized administration. This study explored DDIs and initial dose recommendation of quetiapine in depression patients based on real-world data.

METHODS

Sixty-four real-world depression patients were used to investigate the effects of drug combinations on quetiapine using a non-linear mixed effect model (NONMEM).

RESULTS

In the final model, paroxetine and fluvoxamine were included as covariates, which significantly affected the clearance rate of quetiapine, with ratios of about 1.00:0.54:0.48:0.26 in patients with depression who were not accompanied by paroxetine or fluvoxamine, patients with depression who were accompanied by paroxetine, patients with depression who were accompanied by fluvoxamine, and patients with depression who were accompanied by paroxetine and fluvoxamine. Furthermore, the initial dose optimizations of quetiapine were 20 and 16 mg/kg/day for depression patients not accompanied by paroxetine or fluvoxamine who weighted 40-80, and 80-120 kg, respectively. The initial dose of quetiapine was 8 mg/kg/day for depression patients accompanied by paroxetine who weighted 40-120 kg. The initial dose of quetiapine was 8 mg/kg/day for depression patients accompanied by fluvoxamine, who weighted 40-120 kg. The initial dose optimization of quetiapine was 4 mg/kg/day for depression patients accompanied by paroxetine and fluvoxamine who weighted 40-120 kg.

CONCLUSION

Our study explored DDIs and initial dose recommendation of quetiapine in depression patients from the real world, and the initial dose optimization of quetiapine was recommended based on the interaction with paroxetine or fluvoxamine.